Cardiac Defibrillator Implant without MCC DRG Reimbursement

DRG 277 pertains to inpatient admissions for cardiac defibrillator implantations without Major Complication or Comorbidity, covering device placement and related perioperative care. This Diagnosis-Related Group matters for inpatient reimbursement because it standardizes payment for these procedures under Medicare and hinges on precise coding of procedures and comorbid conditions.

DRG 277 Overview

DRG 277 covers inpatient admissions for cardiac implantable electronic device placement specifically for defibrillator implantation when no Major Complication or Comorbidity is present. Typical cases include primary or replacement single- or dual-lead implantable cardioverter defibrillators without significant additional diagnoses that would elevate severity. This Diagnosis-Related Group is important because it groups similar resource use and directly affects Medicare inpatient payment rates for hospitals. Accurate coding of procedures and comorbidities determines assignment to this Diagnosis-Related Group and associated reimbursement.

Acute procedural and perioperative optimization studies: Trials in this area evaluate strategies to reduce perioperative complications and optimize implantation techniques for patients receiving implantable cardioverter-defibrillators (ICDs) without major complications or comorbid complications (the typical DRG 277 population). These studies enroll patients undergoing first-time or replacement transvenous ICD implantation and compare procedural approaches (e.g., lead placement strategies, anesthesia protocols, infection prophylaxis bundles) and perioperative monitoring to reduce bleeding, infection, and lead-related issues. Results are directly relevant to hospital clinicians and payers because improvements that shorten length of stay, lower complication rates, and reduce readmissions can decrease inpatient resource utilization for this DRG.
Comparative effectiveness and device selection research: This research compares different device types, programming strategies, or implantation routes (e.g., single- versus dual-lead systems, subcutaneous versus transvenous approaches when applicable, and differing shock/anti-tachycardia programming) in patients eligible for ICDs who do not have major complicating comorbidities. Studies focus on outcomes such as inappropriate shocks, need for reintervention, battery longevity, and patient-reported quality of life over intermediate follow-up, enrolling both primary and secondary prevention populations without MCCs. Findings guide clinicians and payers on which device choices and programming approaches offer the best balance of clinical benefit, reduced downstream procedures, and cost-effectiveness for the typical DRG 277 cohort.
Post-discharge outcomes, remote monitoring, and care transition trials: These trials examine strategies to improve post-implant ambulatory management in patients discharged after uncomplicated ICD implantation, testing interventions such as structured remote monitoring protocols, standardized discharge education and follow-up pathways, or nurse-led remote care to detect device issues and arrhythmia events earlier. They enroll patients with recent ICD implantation who are clinically stable at discharge and measure outcomes like unplanned clinic visits, emergency department use, readmissions, and patient adherence to follow-up. This research is important to providers and payers because effective post-discharge surveillance and care coordination can reduce avoidable utilization and costs associated with late complications or device-related events in this DRG.

Acute procedural and perioperative optimization studies: Trials in this area evaluate strategies to reduce perioperative complications and optimize implantation techniques for patients receiving implantable cardioverter-defibrillators (ICDs) without major complications or comorbid complications (the typical DRG 277 population). These studies enroll patients undergoing first-time or replacement transvenous ICD implantation and compare procedural approaches (e.g., lead placement strategies, anesthesia protocols, infection prophylaxis bundles) and perioperative monitoring to reduce bleeding, infection, and lead-related issues. Results are directly relevant to hospital clinicians and payers because improvements that shorten length of stay, lower complication rates, and reduce readmissions can decrease inpatient resource utilization for this DRG.
Comparative effectiveness and device selection research: This research compares different device types, programming strategies, or implantation routes (e.g., single- versus dual-lead systems, subcutaneous versus transvenous approaches when applicable, and differing shock/anti-tachycardia programming) in patients eligible for ICDs who do not have major complicating comorbidities. Studies focus on outcomes such as inappropriate shocks, need for reintervention, battery longevity, and patient-reported quality of life over intermediate follow-up, enrolling both primary and secondary prevention populations without MCCs. Findings guide clinicians and payers on which device choices and programming approaches offer the best balance of clinical benefit, reduced downstream procedures, and cost-effectiveness for the typical DRG 277 cohort.
Post-discharge outcomes, remote monitoring, and care transition trials: These trials examine strategies to improve post-implant ambulatory management in patients discharged after uncomplicated ICD implantation, testing interventions such as structured remote monitoring protocols, standardized discharge education and follow-up pathways, or nurse-led remote care to detect device issues and arrhythmia events earlier. They enroll patients with recent ICD implantation who are clinically stable at discharge and measure outcomes like unplanned clinic visits, emergency department use, readmissions, and patient adherence to follow-up. This research is important to providers and payers because effective post-discharge surveillance and care coordination can reduce avoidable utilization and costs associated with late complications or device-related events in this DRG.

OpenPayer

Summary & Overview

Cardiac Defibrillator Implant without MCC: Inpatient Reimbursement Overview

DRG 277 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes